Laurocapram, a transdermal enhancer, boosts cephalosporin’s antibacterial activity against Methicillin-resistant Staphylococcus aureus
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Nan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China; State Key Laboratory for Diagnosis and Treatment of …. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Cephalosporins, Microbial Sensitivity Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA), a notorious bacterium with high drug resistance and easy recurrence after surgery, has posed significant clinical treatment challenges. In the current scarcity of new antibiotics, the identification of adjuvants to existing antibiotics is a promising approach to combat infections caused by multidrug-resistant Gram-positive bacteria. The in vitro synergy test, which included a MIC assay, time-kill curve, antimicrobial susceptibility testing, and live/dead bacteria staining assay, revealed that laurocapram, a widely used chemical transdermal enhancer, could potentiate the antibacterial activity of cephalosporins against MRSA. In vitro, laurocapram combined with cefixime showed an excellent synergistic activity against MRSA (FICI = 0.28 ± 0.00). In addition, the combination of laurocapram and cefixime may inhibited the formation of MRSA biofilm and caused cell membrane damage. Following that, we discovered that combining laurocapram with cefixime could alleviate the symptoms of mice in the MRSA skin infection model and the MRSA pneumonia model. In conclusion, laurocapram is a promising and low-cost antibacterial adjuvant, providing a new strategy for further exploring the use of lower doses of cephalosporins to combat MRSA infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China; State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Resea…
- Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, Jilin, China.
- State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jili…
- Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in the Western China, and School of Life Sciences, Ningxia University, Yinchuan, China.
- College of Life Science, Jilin Agricultural University, 130118 Changchun, China.
- Jilin Mushuo Breeding Co., Ltd, Changchun 130052, Jilin, China.
Zitieren
APA
Wang, N., Li, W., Yu, H., Huang, W., Qiao, Y., Wang, Q., Wei, Y., Deng, X., Wang, J., Cui, M., Zhang, P., & Zhou, Y. (2024). Laurocapram, a transdermal enhancer, boosts cephalosporin’s antibacterial activity against Methicillin-resistant Staphylococcus aureus. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116404
Vancouver
Wang N, Li W, Yu H, Huang W, Qiao Y, Wang Q, et al. Laurocapram, a transdermal enhancer, boosts cephalosporin’s antibacterial activity against Methicillin-resistant Staphylococcus aureus. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116404
BibTeX
@article{Wang2024,
author = {Wang, Nan and Li, Wei and Yu, Hui and Huang, Wenlin and Qiao, Yarui and Wang, Qi and Wei, Yunfei and Deng, Xuming and Wang, Jianfeng and Cui, Minhe and Zhang, Peng and Zhou, Yonglin},
title = {Laurocapram, a transdermal enhancer, boosts cephalosporin’s antibacterial activity against Methicillin-resistant Staphylococcus aureus},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116404}
}
EUVIMED